🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share our new review on Proximity-Based Modalities for Biology and Medicine | Just out ASAP in ACS Central Science ACS Central Science pubs.acs.org/doi/10.1021/ac…

Xingui Liu and I delve into various modes of actions being pursued, not just PROTACs and molecular glue degraders but also stabilisers, modulators of protein post-translational modifications, cellular localisation, and agents for cell therapy.

Frequency of HER2 alterations across tumor types & current development landscape of HER2-targeted therapies summarized in this publication. nature.com/articles/s4157…

Excited to share a commentary on emerging challenges in understanding and targeting cancer genome instability to improve patient outcomes: bit.ly/3XoSstk Thanks to Cancer Discovery for the opportunity and to everyone else from the AACR NextGen Stars Program who contributed!

Happy to share an article from a friend Jun Hee Lee group. The method paper makes the cell type identification much more accurate for spatial transcriptomics: FICTURE: scalable segmentation-free analysis of submicron-resolution spatial transcriptomics pubmed.ncbi.nlm.nih.gov/39266749/

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy | Science science.org/doi/10.1126/sc…

👥 TALKING HeaDS 👥 An afternoon of data science, snacks, and networking! Join us for "Why are Crystal Structures of Drugs Important?" by Anders Østergaard Madsen. Learn about computational and machine learning methods in drug design! 🗓 5 Nov 👉 RSVP: heads.ku.dk/calendar/2024/…

The hallmarks of cancer immune evasion dlvr.it/TG8BBS

📣 ESMO #ClinicalPracticeGuideline eUpdate on #BiliaryTractCancer in a rapidly evolving landscape: new recommendations on #moleculardiagnostics, local therapies for locally advanced tumours and systemic therapies for recurrent/metastatic disease. #ESMOGuidelines 🔗

Thanks🙏🏼 to our contributors and my co-editors for bringing this 📕 on GB cancer 🦀 in 2025. OHSU Knight Cancer Institute Society of Surgical Oncology IHPBA Cholangiocarcinoma Foundation link.springer.com/book/978303176…

Finding the Right Partner: Triplet Therapy for 1st line Biliary Tract Cancers @JCO doi.org/10.1200/JCO-24… 👉 SWOG-1815 was 🚫 despite promising phs-2 data 👉 Is there still a role of triplet CTx in BTC? 👉 Downstaging, neoadjuvant? 🧐 Summary of recent trials, food for

Cytokines in cancer dlvr.it/THNKt5

nature.com/articles/s4158… Mechanistically, KMT2D localized to active enhancers and CpG-poor promoters that preferentially regulate the urothelial lineage program. CpG-poor promoters-> generally tissue spec promoters Enhancers->generally CpG-poor -> tissue spec expression 😀

Cancer immunotherapy

💚💛

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer NEJM doi.org/10.1056/NEJMoa… 🔎Ph2-2, 204 pts, 12 tumor types 👉 bispecific antibody against HER2 & HER3, 👉ORR 30%, DoR 11.1 mo, mPFS 6.8 mo 👉ORR 40% in #PDAC, 20% in BTC 🧐Effective.. ESMO - Eur. Oncology EASL Education ILCA

Interested in precision medicine and #BTC #cholangiocarcinoma? Read our paper ESMO Open! authors.elsevier.com/sd/article/S20…

Delighted to share a step-by-step protocol for spatially resolved epigenome-transcriptome co-sequencing to map tissue development, aging & disease. Fully committed to open science!! ⁦SenNet Consortium⁩ ⁦Human BioMolecular Atlas Program (HuBMAP)⁩ ⁦NIH Common Fund⁩ @NCIHTAN nature.com/articles/s4159…

Thrilled to share our latest study just out in nature 😄A major milestone in our collaboration with ⁦Anirban Maitra⁩ Led by brilliant ⁦⁦⁦Guangsheng Pei⁩ ⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦⁦Jimin Min⁩ ⁦⁦MD Anderson Cancer Center⁩ nature.com/articles/s4158…

A new study in Nature challenges long-standing views on how Group 3/4 #medulloblastomas develop. Study group led by Prof. S. Pfister argue that large-scale chromosomal alterations, not oncogene mutations, are the earliest events in tumor initiation. 🧵🧵🧵 1/n